Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Cytokinetics, Incorporated (NASDAQ:CYTK). In a filing disclosed on July 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in Cytokinetics stock on June 30th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of The Descartes Systems Group (NASDAQ:DSGX) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of Texas Roadhouse (NASDAQ:TXRH) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of Texas Capital Bancshares (NASDAQ:TCBI) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of RBC Bearings (NYSE:RBC) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of Microchip Technology (NASDAQ:MCHP) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of CECO Environmental (NASDAQ:CECO) on 6/30/2026.

Cytokinetics Stock Performance

Shares of NASDAQ CYTK remained flat at $86.49 during midday trading on Friday. 2,022,530 shares of the company were exchanged, compared to its average volume of 2,483,229. The stock has a 50 day moving average price of $74.97 and a 200 day moving average price of $67.74. Cytokinetics, Incorporated has a twelve month low of $32.89 and a twelve month high of $88.31. The stock has a market capitalization of $10.76 billion, a P/E ratio of -12.64 and a beta of 0.42.

Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.67). The business had revenue of $19.36 million for the quarter, compared to the consensus estimate of $8.52 million. The company’s quarterly revenue was up 1112.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.36) earnings per share. Research analysts anticipate that Cytokinetics, Incorporated will post -6.26 EPS for the current year.

Insider Activity

In related news, EVP Andrew Callos sold 15,857 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $65.00, for a total transaction of $1,030,705.00. Following the transaction, the executive vice president owned 58,555 shares of the company’s stock, valued at approximately $3,806,075. This trade represents a 21.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 7,500 shares of Cytokinetics stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $59.62, for a total transaction of $447,150.00. Following the completion of the sale, the chief executive officer owned 407,830 shares of the company’s stock, valued at $24,314,824.60. This trade represents a 1.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 143,985 shares of company stock worth $10,403,417. Insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Seven Fleet Capital Management LP increased its stake in shares of Cytokinetics by 492.8% in the first quarter. Seven Fleet Capital Management LP now owns 61,269 shares of the biopharmaceutical company’s stock worth $4,038,000 after acquiring an additional 50,934 shares during the last quarter. Western Wealth Management LLC acquired a new stake in Cytokinetics during the first quarter valued at $53,000. Cim Investment Management Inc. acquired a new stake in Cytokinetics during the first quarter valued at $308,000. Janus Henderson Group PLC grew its stake in Cytokinetics by 10.1% in the first quarter. Janus Henderson Group PLC now owns 282,121 shares of the biopharmaceutical company’s stock valued at $18,593,000 after purchasing an additional 25,909 shares in the last quarter. Finally, Encore Global Management LP purchased a new position in Cytokinetics in the first quarter valued at about $330,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. UBS Group raised Cytokinetics from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $69.00 to $115.00 in a research note on Monday. Leerink Partners restated an “outperform” rating on shares of Cytokinetics in a report on Tuesday, March 10th. Royal Bank Of Canada restated an “outperform” rating and issued a $119.00 price target on shares of Cytokinetics in a research report on Wednesday, June 17th. Needham & Company LLC reaffirmed a “buy” rating and issued a $102.00 price objective on shares of Cytokinetics in a research note on Wednesday, June 17th. Finally, Barclays increased their target price on Cytokinetics from $87.00 to $95.00 and gave the company an “overweight” rating in a report on Monday, April 6th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $100.00.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Cytokinetics

Cytokinetics, Inc is a late?stage biopharmaceutical company focused on the discovery and development of novel small?molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.